Liao Rui, Wang Long, Zeng Jing, Tang Xiaoqin, Huang Miao, Kantawong Fahsai, Huang Qianqian, Mei Qibing, Huang Feihong, Yang Yan, Liao Bin, Wu Anguo, Wu Jianming
Sichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, 646000, China; School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, China.
Sichuan Key Medical Laboratory of New Drug Discovery and Druggability, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, 646000, China.
Redox Biol. 2025 Mar;80:103489. doi: 10.1016/j.redox.2025.103489. Epub 2025 Jan 3.
Platelets, which are vital for blood clotting and immunity, need to maintain a delicately balanced relationship between generation and destruction. Recent studies have highlighted that reactive oxygen species (ROS), which act as second messengers in crucial signaling pathways, are crucial players in this dance. This review explores the intricate connection between ROS and platelets, highlighting their dual nature. Moderate ROS levels act as potent activators, promoting megakaryocyte (MK) differentiation, platelet production, and function. They enhance platelet binding to collagen, increase coagulation, and directly trigger cascades for thrombus formation. However, this intricate role harbors a double-edged sword. Excessive ROS unleash its destructive potential, triggering apoptosis and reducing the lifespan of platelets. High levels can damage stem cells and disrupt vital redox-dependent signaling, whereas uncontrolled activation promotes inappropriate clotting, leading to thrombosis. Maintaining a precise balance of ROS within the hematopoietic microenvironment is paramount for optimal platelet homeostasis. While significant progress has been made, unanswered questions remain concerning specific ROS signaling pathways and their impact on platelet disorders. Addressing these questions holds the key to unlocking the full potential of ROS-based therapies for treating platelet-related diseases such as thrombocytopenia and thrombosis. This review aims to contribute to this ongoing dialog and inspire further exploration of this exciting field, paving the way for novel therapeutic strategies that harness the benefits of ROS while mitigating their dangers.
血小板对于血液凝固和免疫至关重要,需要在生成与破坏之间维持一种微妙的平衡关系。最近的研究强调,作为关键信号通路中第二信使的活性氧(ROS),是这一过程中的关键参与者。本综述探讨了ROS与血小板之间的复杂联系,突出了它们的双重性质。适度的ROS水平作为强效激活剂,促进巨核细胞(MK)分化、血小板生成及功能。它们增强血小板与胶原蛋白的结合,增加凝血作用,并直接触发血栓形成的级联反应。然而,这一复杂作用犹如一把双刃剑。过量的ROS释放其破坏潜力,引发细胞凋亡并缩短血小板寿命。高水平的ROS会损害干细胞并扰乱重要的氧化还原依赖性信号传导,而不受控制的激活则会促进不适当的凝血,导致血栓形成。在造血微环境中维持ROS的精确平衡对于实现最佳的血小板稳态至关重要。虽然已经取得了重大进展,但关于特定的ROS信号通路及其对血小板疾病的影响仍存在未解决的问题。解决这些问题是释放基于ROS的疗法治疗血小板相关疾病(如血小板减少症和血栓形成)全部潜力的关键。本综述旨在为这一持续的讨论做出贡献,并激发对这一令人兴奋领域的进一步探索,为利用ROS的益处同时减轻其危险的新型治疗策略铺平道路。